Vanderbilt University is 100th Facility to Install Genetix’ ClonePix FL
News Apr 27, 2010
Genetix announces that Vanderbilt Monoclonal Antibody Core (VMAC), Vanderbilt University, has become the 100th facility to purchase its ClonePix™ FL system.
Used for screening and selection of secretory cell lines, the ClonePix FL system can significantly reduce the time and costs associated with recombinant protein generation. VMAC will use the system to support its monoclonal and polyclonal antibody generation, purification, and characterization technical advice and services, and also its recombinant protein production and purification services.
Dr. Robert Carnahan, Director, VMAC, said: “Our aim at VMAC is to provide a centre of expertise in all areas of monoclonal antibody production and recombinant protein technology. It is vital that we are able to access state of the art technology such as the ClonePix FL system, in order to provide the best service for investigators both within Vanderbilt and beyond.”
Charles de Rohan, Head of the Genetix Business Unit within Leica Microsystems, commented: “We’re delighted that the benefits of ClonePix FL systems are recognized by so many laboratories. The VMAC is a highly prestigious institute and its decision to invest in this technology is testament to the value it brings to antibody and recombinant protein production.”
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018